Related Experiment Video

Updated: Jul 19, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

Antonio Jimeno1, Manuel Hidalgo

  • 1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, The Bunting-Blaustein Cancer Research Building, Room 1M88, 1650 Orleans Street, Baltimore, MD 21231-1000, USA.

Biochimica Et Biophysica Acta
|October 19, 2006
PubMed

Insights

Genetic factors influence response to epidermal growth factor receptor (EGFR) inhibitors in cancer. Understanding EGFR gene variations, like amplifications and polymorphisms, is key to personalized cancer therapy and predicting treatment efficacy.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) is a crucial target in cancer therapy, with targeted agents integrated into treatment protocols.
  • Patient responses to EGFR-targeted therapies vary significantly, often linked to underlying genetic factors.
  • EGFR amplifications and specific genetic polymorphisms influence sensitivity and outcomes in various cancers.

Purpose of the Study:

  • To review the background and current preclinical and clinical data on the pharmacogenomics of EGFR tyrosine kinase inhibitors.
  • To discuss the role of EGFR genetic variations in cancer treatment response.
  • To explore the evolving landscape of EGFR-targeted therapies and their personalized application.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of clinical trial data.
  • Examination of genetic polymorphism and mutation data related to EGFR.

Main Results:

  • EGFR amplifications enhance sensitivity to EGFR inhibitors.
  • An EGFR intron 1 CA repeat polymorphism impacts EGFR expression and is associated with familial breast cancer risk, colorectal cancer outcomes, and preclinical anti-EGFR efficacy.
  • EGFR activating mutations in lung cancer show variable correlation with tyrosine kinase inhibitor sensitivity, while efficacy is observed even in EGFR-mutation-negative cancers like pancreatic cancer.

Conclusions:

  • Pharmacogenomic insights into EGFR are rapidly advancing, particularly for tyrosine kinase inhibitors.
  • Genetic variations in EGFR play a significant role in predicting and understanding patient response to targeted therapies.
  • Personalized treatment strategies based on EGFR genetic profiles hold promise for improving cancer outcomes.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...